Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H35NO2 |
Molecular Weight | 321.4974 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]3(C)CC[C@H](O)C[C@@H]3CO
InChI
InChIKey=MDEJTPWQNNMAQF-BVMLLJBZSA-N
InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1
Molecular Formula | C20H35NO2 |
Molecular Weight | 321.4974 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Rosiptor (AQX-1125) is a once daily, orally administered small molecule being developed by Aquinox Pharmaceuticals for the treatment of asthma, bladder pain syndrome/interstitial cystitis (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome. AQX-1125 is the only clinical-stage, orally administered, SHIP1 activator. AQX-1125 significantly reduces the late response to allergen challenge, with a trend to reduce airway inflammation. AQX-1125 was safe and well tolerated and merits further investigation in inflammatory disorders. AQX-1125 has been used in trials studying the treatment of COPD, atopic dermatitis, interstitial cystitis, and bladder pain syndrome. However, the development has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25040039
AQX-1125 (450 mg daily) was administered orally for 7 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23121445
At 0.1 uM AQX-1125 the inhibition amounted to an average of 34%, while at 10 uM the inhibition amounted to an average of 82% in two independent experiments. Similarly, AQX-1125 exerted a dose-dependent inhibition of Akt phosphorylation in SHIP+/+mouse splenic lymphocytes, with a maximal inhibitory effect at 30 uM amounting to 73% and 82% in T-cells and B cells, respectively as measured by Luminex analysis
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:39:49 GMT 2023
by
admin
on
Sat Dec 16 08:39:49 GMT 2023
|
Record UNII |
6R5034F862
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1404
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
782487-28-9
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
PRIMARY | |||
|
100000174652
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
PRIMARY | |||
|
DB13012
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
PRIMARY | |||
|
10126
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
PRIMARY | |||
|
C152258
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
PRIMARY | |||
|
76965484
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
PRIMARY | |||
|
EF-69
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
PRIMARY | |||
|
6R5034F862
Created by
admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> ACTIVATOR |
BINDING
Km
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |